These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 31685553

  • 1. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups.
    Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
    [Abstract] [Full Text] [Related]

  • 2. Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
    Kiltz U, Wei JC, van der Heijde D, van den Bosch F, Walsh JA, Boonen A, Gensler LS, Hunter T, Carlier H, Dong Y, Li X, Bolce R, Strand V, Braun J.
    J Rheumatol; 2021 Feb; 48(2):188-197. PubMed ID: 32669450
    [Abstract] [Full Text] [Related]

  • 3. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
    van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H, COAST-V study group.
    Lancet; 2018 Dec 08; 392(10163):2441-2451. PubMed ID: 30360964
    [Abstract] [Full Text] [Related]

  • 4. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
    van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M.
    Adv Ther; 2022 Jun 08; 39(6):2806-2819. PubMed ID: 35429281
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
    Landewé RB, Gensler LS, Poddubnyy D, Rahman P, Hojnik M, Li X, Liu Leage S, Adams D, Carlier H, Van den Bosch F, COAST-Y study group.
    Ann Rheum Dis; 2021 Aug 08; 80(8):1022-1030. PubMed ID: 33958326
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
    Deodhar AA, Mease PJ, Rahman P, Navarro-Compán V, Strand V, Hunter T, Bolce R, Leon L, Lauzon S, Marzo-Ortega H.
    BMC Rheumatol; 2021 Sep 20; 5(1):35. PubMed ID: 34538257
    [Abstract] [Full Text] [Related]

  • 9. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
    Maksymowych WP, Bolce R, Gallo G, Seem E, Geneus VJ, Sandoval DM, Østergaard M, Tada K, Baraliakos X, Deodhar A, Gensler LS.
    Rheumatology (Oxford); 2022 Nov 02; 61(11):4324-4334. PubMed ID: 35188180
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program.
    Deodhar A, Poddubnyy D, Rahman P, Ermann J, Tomita T, Bolce R, Leage SL, Kronbergs A, Johnson C, Araújo J, Leung A, van der Heijde D.
    J Rheumatol; 2023 Aug 02; 50(8):1020-1028. PubMed ID: 36792107
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ.
    J Rheumatol; 2018 Mar 02; 45(3):367-377. PubMed ID: 29247148
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
    Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD, COAST-W Study Group.
    Arthritis Rheumatol; 2019 Apr 02; 71(4):599-611. PubMed ID: 30343531
    [Abstract] [Full Text] [Related]

  • 14. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
    Maksymowych WP, Baraliakos X, Lambert RG, Landewé R, Sandoval D, Carlier H, Lisse J, Li X, Hojnik M, Østergaard M.
    Lancet Rheumatol; 2022 Sep 02; 4(9):e626-e634. PubMed ID: 38288892
    [Abstract] [Full Text] [Related]

  • 15. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P.
    J Eur Acad Dermatol Venereol; 2017 Mar 02; 31(3):477-482. PubMed ID: 27910156
    [Abstract] [Full Text] [Related]

  • 16. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
    Xue Y, Hu J, Liu D, Li J, Wu H, Tan C, Dai L, Sun L, Li Z, Xiao Z, Huang C, Yan Y, Ji F, Chen R, Zou H.
    BioDrugs; 2024 Jan 02; 38(1):145-156. PubMed ID: 37737952
    [Abstract] [Full Text] [Related]

  • 17. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.
    Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H.
    Rheumatol Ther; 2019 Sep 02; 6(3):435-450. PubMed ID: 31254223
    [Abstract] [Full Text] [Related]

  • 18. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
    van der Heijde D, Østergaard M, Reveille JD, Baraliakos X, Kronbergs A, Sandoval DM, Li X, Carlier H, Adams DH, Maksymowych WP.
    J Rheumatol; 2022 Mar 02; 49(3):265-273. PubMed ID: 34853086
    [Abstract] [Full Text] [Related]

  • 19. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C.
    J Eur Acad Dermatol Venereol; 2017 Jul 02; 31(7):1196-1207. PubMed ID: 28370467
    [Abstract] [Full Text] [Related]

  • 20. Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis.
    Ramiro S, Lukas C, Bessette L, Wickersham P, Panni T, Bolce R, Liu-Leage S, Janos B, Nissen MJ, Wei JC.
    RMD Open; 2024 Jul 14; 10(3):. PubMed ID: 39004432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.